SAGIMET BIOSCIENCES IN

5.5400

27-November-24 16:45:00

15 minutes delayed

Stocks

+0.3700

+7.16%

Today's range

5.1900 - 5.6470

ISIN

N/A

Source

NASDAQ

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

27 Mar 2024 16:01:00 By Nasdaq GlobeNewswire
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

25 Mar 2024 07:00:00 By Nasdaq GlobeNewswire
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

25 Mar 2024 06:15:00 By Nasdaq GlobeNewswire
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

29 Feb 2024 08:00:00 By Nasdaq GlobeNewswire
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

25 Jan 2024 20:58:03 By Nasdaq GlobeNewswire
Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

23 Jan 2024 17:45:51 By Nasdaq GlobeNewswire
Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

22 Jan 2024 07:00:00 By Nasdaq GlobeNewswire
Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

04 Dec 2023 08:00:01 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.